Azithromycin use in clinical practice

S.O. Kramarov, V.V. Yevtushenko

Abstract


Azithromycin is an antibiotic, which is usually used to treat infections of the upper and lower respiratory tract in children. Despite its high popularity, concerns have been raised regarding the increasing resistance of respiratory pathogens to this drug in recent years. The pharmacokinetics, spectrum of activity, the problem of resistant bacteria and clinical aspects, as well as recommendations on the use are considered. Azithromycin is recommended as an antibiotic of choice for empirical therapy and selective therapy of major bacterial pathogens of acute intestinal infections in children, for etiotropic treatment of whooping cough, with Lyme disease and for long-term immunomodulatory therapy of cystic fibrosis.

Keywords


azithromycin; infections; treatment

References


World Health Organization.Macrolides (Review).In: Proceeding of the Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. 2008 Sept 29 – Oct 3; Geneva, Switzerland.Available from: http://www.who.int/selection_medicines/committees/subcommittee/2/macrolides/en/.

Azithromycin.Available from: https://www.drugs.com/azithromycin.html. Accessed: September 29, 2017.

McMullan BJ, Mostaghim M.Prescribing azithromycin.Aust Prescr. 2015 Jun;38(3):87-9.

Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R.Azithromycin: mechanisms of action and their relevance for clinical applications.Pharmacol Ther. 2014 Aug;143(2):225-45. doi: 10.1016/j.pharmthera.2014.03.003.

Omura S, editor.Macrolide Antibiotics.Chemistry, Biology, and Practice. 2nd ed.San Diego:Academic Press; 2002. 635 p.

Ovetchkine P, Rieder MJ; CanadianPaediatricSociety, DrugTherapyandHazardousSubstancesCommittee.Azithromycinuseinpaediatrics: A practicaloverview.PaediatrChildHealth. 2013 Jun;18(6):311-6.

Lieberthal AS, Carroll AE, Chonmaitree T,et al.The diagnosis and management of acute otitis media.Pediatrics. 2013 Mar;131(3):e964-99. doi: 10.1542/peds.2012-3488.

Schaad UB, Kellerhals P, Altwegg M; Swiss Pharyngitis Study Group.Azithromycin versus penicillin V for treatment of acute group A streptococcal pharyngitis.Pediatr Infect Dis J. 2002 Apr;21(4):304-8.

Michelow IC, Olsen K, Lozano J, et al.Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children.Pediatrics. 2004 Apr;113(4):701-7.

Kurz H, Göpfrich H, Huber K, et al. Spectrum of pathogens of in-patient children and youths with community acquired pneumonia: a 3 year survey of a community hospital in Vienna, Austria. Wien Klin Wochenschr. 2013 Nov;125(21-22):674-9. doi: 10.1007/s00508-013-0426-z. 

Bradley JS, Byington CL, Shah SS, et al. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011 Oct;53(7):617-30. doi: 10.1093/cid/cir625.

Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis. 2000 Oct;31(4):1008-11. doi: 10.1086/318157.

Guarino A, Ashkenazi S, Gendrel D, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr. 2014 Jul;59(1):132-52. doi: 10.1097/MPG.0000000000000375.

Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017 Nov 29;65(12):1963-1973. doi: 10.1093/cid/cix959.

Brown JD, Willcox SJ, Franklin N, et al. Shigella species epidemiology and antimicrobial susceptibility: the implications of emerging azithromycin resistance for guiding treatment, guidelines and breakpoints. J Antimicrob Chemother. 2017 Nov 1;72(11):3181-3186. doi: 10.1093/jac/dkx268.

Darton TC, Tuyen HT, The HC, et al. Azithromycin Resistance in Shigella spp. in Southeast Asia. Antimicrobial Agents and Chemotherapy. 2018;62(4):e01748-17. doi:10.1128/AAC.01748-17.

Vlieghe ER, Phe T, De Smet B,et al. Azithromycin and ciprofloxacin resistance in Salmonella bloodstream infections in Cambodian adults. PLoS Negl Trop Dis. 2012;6(12):e1933. doi: 10.1371/journal.pntd.0001933.

Hassing R-J, Goessens WHF, van Pelt W, et al. SalmonellaSubtypes with Increased MICs for Azithromycin in Travelers Returned to the Netherlands. Emerging Infectious Diseases. 2014;20(4):705-708. doi:10.3201/eid2004.131536.

Mukherjee P, Ramamurthy T, Mitra U, Mukhopadhyay AK. Emergence of High-Level Azithromycin Resistance in Campylobacter jejuni Isolates from Pediatric Diarrhea Patients in Kolkata, India. Antimicrobial Agents and Chemotherapy. 2014;58(7):4248. doi:10.1128/AAC.02931-14.

Fry NK, Duncan J, Vaghji L, George RC, Harrison TG. Antimicrobial susceptibility testing of historical and recent clinical isolates of Bordetella pertussis in the United Kingdom using the Etest method. Eur J Clin Microbiol Infect Dis. 2010 Sep;29(9):1183-5. doi: 10.1007/s10096-010-0976-1. 

Jakubů V, Zavadilová J, Fabiánová K, Urbášková P. Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015. Cent Eur J Public Health. 2017 Dec;25(4):282-286. doi: 10.21101/cejph.a4948.

Pertussis Guideline Working Group. PHE Guidelines for the Public Health Management of Pertussis. Incidents in Healthcare Settings. London; 2016. 35 p.

Graham L. CDC Releases Guidelines on Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis. Am Fam Physician. 2006 Jul 15;74(2):333-336.

Santino I, Scazzocchio F, Ciceroni L, Ciarrocchi S, Sessa R, Del Piano M. In vitro susceptibility of isolates of Borrelia burgdorferi s.l. to antimicrobial agents. Int J Immunopathol Pharmacol. 2006 Jul-Sep;19(3):545-9. doi: 10.1177/039463200601900310.

Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006 Nov 1;43(9):1089-134. doi: 10.1086/508667.

Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection. 2000 May-Jun;28(3):153-6.

Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Review of Anti-Infective Therapy. 2014;12(9):1103-1135. doi:10.1586/14787210.2014.940900.

National Institute for Health and Care Excellence (NICE). Lyme disease. NG95. Available from: https://www.nice.org.uk/guidance/ng95. Accessed: April 2018.

Hofmann H, Fingerle V, Hunfeld KP, et al. Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society. Ger Med Sci. 2017 Sep 5;15:Doc14. doi: 10.3205/000255. 

Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2012 Nov 14;11:CD002203. doi: 10.1002/14651858.

Emiralioğlu N, Öztürk Z, Yalçın E, Doğru D, Özçelik U, Kiper N. Long term azithromycin therapy in patients with cystic fibrosis. Turk J Pediatr. 2016;58(1):34-40.

Pradal U, Delmarco A, Morganti M, Cipolli M, Mini E, Cazzola G. Long-term azithromycin in cystic fibrosis: another possible mechanism of action? J Chemother. 2005 Aug;17(4):393-400. doi: 10.1179/joc.2005.17.4.393.

Principi N, Blasi F, Esposito S. Azithromycin use in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2015 Jun;34(6):1071-9. doi: 10.1007/s10096-015-2347-4.

National Institute for Health and Care Excellence (NICE). Cystic fibrosis: diagnosis and management. NG78. Available from: https://www.nice.org.uk/guidance/ng78/chapter/recommendations. Accessed: October 2017.

Zupanec I, Bezuglaja N, Libina V, et al. Assessment of the interchangeability of Azimed - bioequivalence has been proved! Liky Ukrai'ny. 2013;(14):57-60. (in Russian).




DOI: https://doi.org/10.22141/2312-413x.6.2.2018.131089

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 ACTUAL INFECTOLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта